The company was established in Asia in China. The leading representative office of defined VC is situated in the Pudong.
The fund has no exact preference in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Among the most successful fund investment fields, there are Life Science, Therapeutics. Among the most popular portfolio startups of the fund, we may highlight Global Switch, Oscar Health Insurance Co., 9f Group. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.
The fund is constantly included in 2-6 investment rounds annually. The average startup value when the investment from Ping An Ventures is more than 1 billion dollars. Opposing the other organizations, this Ping An Ventures works on 16 percentage points less the average amount of lead investments. The real fund results show that this VC is 12 percentage points more often commits exit comparing to other companies. The top amount of exits for fund were in 2019. The top activity for fund was in 2018. The usual things for fund are deals in the range of more than 100 millions dollars.
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Ping An Ventures, startups are often financed by Qiming Venture Partners, Lilly Asia Ventures, GV. The meaningful sponsors for the fund in investment in the same round are Shunwei Capital, SIG China (SIG Asia Investments), Lilly Asia Ventures. In the next rounds fund is usually obtained by IDG Capital, Tencent Holdings, Qiming Venture Partners.
We also calculated 3 valuable employees in our database.
Related Funds
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Xgene Pharmaceutical | $40M | 05 Nov 2021 | Shanghai, China | ||
DentaLink China | 03 Jan 2020 | Shenzhen, Guangdong, China | |||
Zhangshang Tangyi | $100M | 07 Jan 2019 | Shangcheng District, Zhejiang, China | ||
Xiaoqule | $108M | 20 Nov 2018 | Shangcheng District, Zhejiang, China | ||
Global Scanner | $108M | 19 Nov 2018 | China, Zhejiang | ||
NextCure | $93M | 13 Nov 2018 | Maryland, United States | ||
$20M | 25 Oct 2018 | Shanghai | |||
HashFish | $1M | 27 Jul 2018 | Haidian District, Beijing, China | ||
Jollychic | $1B | 28 May 2018 | China, Zhejiang |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Xgene Pharmaceutical | $40M | 05 Nov 2021 | Shanghai, China | ||
DentaLink China | 03 Jan 2020 | Shenzhen, Guangdong, China | |||
Zhangshang Tangyi | $100M | 07 Jan 2019 | Shangcheng District, Zhejiang, China | ||
Xiaoqule | $108M | 20 Nov 2018 | Shangcheng District, Zhejiang, China | ||
Global Scanner | $108M | 19 Nov 2018 | China, Zhejiang | ||
NextCure | $93M | 13 Nov 2018 | Maryland, United States | ||
$20M | 25 Oct 2018 | Shanghai | |||
HashFish | $1M | 27 Jul 2018 | Haidian District, Beijing, China | ||
Jollychic | $1B | 28 May 2018 | China, Zhejiang |